×

Global Follicle Stimulating Hormone Market to Exhibit a Moderate CAGR of 4.2% from 2019 and 2025

 3.0   Star Rating

 Published Date : 21 Jan 20   |   Views: 89   |  Industry : Life Science

Global Follicle Stimulating Hormone Market to Exhibit a Moderate CAGR of 4.2% from 2019 and 2025

QYR Consulting has recently published a report that offers insights on the crucial aspects of the market. Titled, ““Global Follicle Stimulating Hormone Market Report: Company Analysis, History and Future Overview, Global Sales Trends by 2025,” this report provides the dashboard view of the market including new and innovative strategies adopted by the top players functioning in the market. According to this report, As per the report, the global Follicle Stimulating Hormone Market is projected to reach US$ 1.7 Bn by the end of 2025 from US$ 1.2 Bn in 2018, exhibiting a moderate CAGR of 4.2% over the forecasted period i.e. from 2019 to 2025.

Segmental Analysis

Cost-effective Urinary FSH is likely to Boost the Growth of the Urinary FSH Segment

The product segment is divided into Urinary FSH and Recombinant FSH. Both Urinary FSH and Recombinant FSH are frequently used in ovarian stimulation, although several studies have stated their effectiveness to be similar. The urinary preparation FSH is said to be more cost-effective than the other, which is likely to benefit the growth of Urinary FSH segment. The application segment is classified into Assisted Reproductive Technology and Infertility treatment.

Global Follicle Stimulating Hormone Market to Exhibit a Moderate CAGR of 4.2% from 2019 and 2025

Europe

Global Follicle Stimulating Hormone Market to Exhibit a Moderate CAGR of 4.2% from 2019 and 2025

Regional Analysis


High Rate of Adoption of Follicle Stimulating Hormone Products  to Create Robust Growth in Europe Market  

Due to the high rate of adoption of Follicle Stimulating Hormone products in Europe, the region is expected to grab a remarkable share of the market in the years to come. .  On the other hand a  high rate of infertility in females in North America is driving the growth of the market in the region. 

Key Players


Leading Companies  to Focus on Investing in R&D

Some of the key players operating in the Follicle Stimulating Hormone market are MSD, Merck Serono, IBSA, Livzon, Ferring, Gensci, Techwell, Tev, and Gedeon Richter. The market comprises several players, however, MSD and Merck Serono are top companies generating a substantial amount of market revenue. The market players are keen to invest in R&D to develop new products and to improve patient care.


Global Follicle Stimulating Hormone Market to Exhibit a Moderate CAGR of 4.2% from 2019 and 2025

Global CAGR During 2020-2026


4.2%

Market Dynamics


Growing   Fertility Problems to Foster the Growth of the Global Market

Growing   ratio of infertility both in women and men due to the insufficiency of follicle-stimulating hormone has resulted in increasing  Research and Development activityin the  healthcare sector. Growing usage of  Follicle Stimulating Hormone  for FSH test  to assess infertility problems amongst physicians is likely to foster the growth of the market. Follicle Stimulating Hormone test also helps in diagnosing disorders related to ovaries in the female population, which is contributing to the growth of the market.


For further information, check :https://www.qyrconsulting.com/reports/follicle-stimulating-hormone-market


Ask a Question

Get in touch with us to find answers to all your business-related queries for fast results.

  Thank you for sharing your rating with us.